Join #ThisIsOurShot Campaign
1. Join our #PWChat on Twitter, January 21 at 6:30pm EST to learn more! 2. Sign up to be added to...
Read More
Author: Janine Anthes
PhysQuiz Answers! ASCO GU: Renal Cell Carcinoma
1) Results released from the Phase 3 CLEAR Trial found that lenvatinib combined with EITHER of these two drugs demonstrated significant benefits over sunitinib in patients with advanced RCC: a) pembrolizumab or...
Read More
Physicians Say Onset, Duration of Action & Ease of Use Increase Treatment Compliance in Patients With Obstructive Pulmonary Diseases Physicians Say Onset, Duration of Action & Ease of Use Increase Treatment Compliance in Patients With Obstructive Pulmonary Diseases
Onset and duration of action and ease of use were classified higher as important parameters to...
Read More
Study Finds Preferences for Inhaler Attributes in Patients With COPD
atient preference data for maintenance inhaler attributes can be used to identify a preference...
Read MoreSABCS 2020: First Immunotherapy Combo Well-Tolerated
In an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...
Read MoreSABCS 2020: Update from the DESTINY-Breast01 trial
In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer taking antibody-drug conjugate trastuzumab deruxtecan continued to demonstrate favorable efficacy data, durable...
Read MoreAHA 2020: Polypill Plus Aspirin Prevents Cardiovascular Events
Participants without cardiovascular disease but who were at increased risk were randomly assigned to receive a polypill (i.e. 1 statin with 3 blood pressure-lowering drugs) or placebo and to receive aspirin or placebo. With 4.6...
Read MoreAHA 2020: PCSK9 inhibition as primary prevention for VTE: Is it LDL or Lp(a)?
Physician’s Weekly spoke with first author Nicholas A. Marston, MD, an Associate Physician in the Cardiovascular Division at Brigham and Women’s Hospital (Boston, USA), an Instructor of Medicine at Harvard Medical School, and an...
Read MoreHBM9036 Nasal Spray for Dry Eye Disease
HBM9036 ophthalmic solution 0.25%, also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...
Read MoreImpact of Dry Eye Signs & Symptoms on Work Productivity
Dry eye disease (DED) is a highly prevalent syndrome that manifests with symptoms that include constant irritation, burning or stinging sensations, and feelings of grittiness in the eyes. “DED is a chronic pain syndrome often...
Read MoreSevere DED in Chronic GVHD: Assessing the Role of Serum Vitamin A
Previous research has shown that patients undergoing hematopoietic stem cell transplantation (HSCT) for hematologic malignancies, such as leukemia and lymphoma, are at a high risk of developing graft-versus-host disease (GVHD)....
Read MoreExamining the Role of Microneuromas Markers in Neuropathic Ocular Pain
Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability. The disease can significantly decrease quality of life as it impacts an...
Read MorePreoperative Dry Eye Diagnosis & Treatment Among Cataract Patients
According to published research, as many as 77% of patients with cataracts present with common signs of dry eye disease (DED) prior to surgery. These signs include corneal staining, short tear breakup time, and hyperosmolarity,...
Read MoreiPredict: A Telemedicine Platform for Screening Patients With Referable AMD
Wide-scale implementation of telemedicine has become increasingly important in a variety of medical fields, including ophthalmology, as the COVID-19 pandemic continues to impact healthcare delivery. It is well known that...
Read MoreAssessing a Novel Contrast Sensitivity Function Test in AMD
Contrast sensitivity is a key metric of visual function that strongly correlates with visual impairment and daily functional vision. Patients with age-related macular degeneration (AMD) often complain of visual dysfunction in...
Read MoreCataract Surgery in Wet AMD: Assessing Outcomes & Complications
Age-related macular degeneration (AMD) continues to be the leading cause of blindness for people aged 60 years and older. For decades, cataract surgery has been controversial in the management of patients with AMD because it...
Read MoreBrolucizumab for Wet AMD: Assessing Profiles & Early Outcomes
Anti-vascular endothelial growth factor (VEGF) therapies have been revolutionary for the treatment of wet age-related macular degeneration (AMD), but unmet needs persist. Despite robust responses and visual gains in many...
Read MoreAHA 2020: Inclisiran effective across age and genders for hyperlipidemia
Recently approved by the European Medicines Association, and currently under review by the US Food and Drug Administration, inclisiran, a first-in-class small interfering RNA (siRNA) treatment, impressively improved primary...
Read MoreAutotaxin inhibition: a fascinating novel treatment approach for cutaneous lupus patients
The autotaxin inhibitor ziritaxestat proved to be efficacious and tolerable in the first randomised, double-blind, placebo-controlled phase 2 trial ever conducted in patients with diffuse cutaneous systemic sclerosis....
Read MoreNew treatment possibility for giant cell arteritis on the horizon
The anti-GM-CSF receptor alpha monoclonal antibody mavrilimumab entailed a lower risk of flare and greater sustained remission compared with placebo in patients with giant cell arteritis. A phase 2, randomised,...
Read More